著者
Masaomi Nangaku Takashi Kadowaki Hiroshi Yotsuyanagi Norio Ohmagari Moritoki Egi Junichi Sasaki Tetsuya Sakamoto Yoshinori Hasegawa Takashi Ogura Shigeru Chiba Koichi Node Ryo Suzuki Yasuhiro Yamaguchi Atsuko Murashima Norihiko Ikeda Eriko Morishita Kenji Yuzawa Hiroyuki Moriuchi Satoshi Hayakawa Daisuke Nishi Atsushi Irisawa Toshiaki Miyamoto Hidetaka Suzuki Hirohito Sone Yuuji Fujino
出版者
Japan Medical Association / The Japanese Associaiton of Medical Sciences
雑誌
JMA Journal (ISSN:2433328X)
巻号頁・発行日
vol.4, no.2, pp.148-162, 2021-04-15 (Released:2021-05-07)
参考文献数
69
被引用文献数
7

In 2020, the COVID-19 pandemic has had unprecedented impacts on various aspects of the world. Each academic society has published a guide and/or guidelines on how to cope with COVID-19 separately. As the one and only nationwide association of academic societies that represent medical science in Japan, JMSF has decided to publish the expert opinion to help patients and care providers find specifically what they want.This expert opinion is a summary of recommendations by many academic societies and will be updated when necessary. Patients that each academic society targets differ even though they suffer from the same COVID-19, and recommendations can be different in a context-dependent manner. Readers are supposed to be flexible and adjustable when they use this expert opinion.
著者
Yoshinori Katsumata Fumiya Sano Takayuki Abe Tomoyoshi Tamura Taishi Fujisawa Yasuyuki Shiraishi Shun Kohsaka Ikuko Ueda Koichiro Homma Masaru Suzuki Shigeo Okuda Yuichiro Maekawa Eiji Kobayashi Shingo Hori Junichi Sasaki Keiichi Fukuda Motoaki Sano
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
vol.81, no.7, pp.940-947, 2017-06-23 (Released:2017-06-23)
参考文献数
28
被引用文献数
18 49

Background:Hydrogen gas inhalation (HI) reduced infarct size and mitigated adverse left ventricular (LV) remodeling in a rat model of acute myocardial infarction (AMI). We designed a prospective, open-label, rater-blinded clinical pilot study in patients experiencing ST-elevated MI (STEMI).Methods and Results:The 20 patients with an initial diagnosis of STEMI were assigned to either an HI group (1.3% H2with 26% oxygen) or a control group (26% oxygen). There were no HI-related severe adverse events. In the full analysis set, the cardiac salvage index as evaluated using cardiac magnetic resonance imaging at 7 days after primary percutaneous coronary intervention (PCI), showed no significant between-group difference (HI: 50.0±24.3%; control: 60.1±20.1%; P=0.43). However, the improvement from day 7 in the HI group was numerically greater than that in the control group in some of the surrogate outcomes at 6-month follow-up, including the LV stroke volume index (HI: 9.2±7.1 mL/m2; control: −1.4±7.2 mL/m2; P=0.03) and the LV ejection fraction (HI: 11.0%±9.3%; control: 1.7%±8.3%; P=0.11).Conclusions:The first clinical study has shown that HI during PCI is feasible and safe and may also promote LV reverse remodeling at 6 months after STEMI. The study was not powered to test efficacy and a further large-scale trial is warranted. (Clinical trials registration: UMIN00006825)